Incyte (INCY – Research Report) received a Hold rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...

Analysts are intrested in these 5 stocks: ( ($MNDY) ), ( ($INCY) ), ( ($LCID) ), ( ($BE) ) and ( ($EQT) ). Here is a ...

Investment analysts at William Blair increased their Q2 2025 EPS estimates for shares of Incyte in a research note issued on Tuesday, March 18th. William Blair analyst M. Phipps now expects that the ...

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...

The Communication Authority of Kenya (CAK) also reduced the rate from Ksh0.99 ($0.0076) per minute to Ksh0.41 ($0.0031) per ...

Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents ...

Incyte (NASDAQ:INCY – Get Free Report) was downgraded by William Blair from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday, Marketbeat.com reports.

In terms of response, it met its primary end point in all 3 doses. 1 The ORR was 50% or higher [in all 3 groups]. The dose of ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...